VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
0.2240
-0.0014 (-0.62%)
At close: Sep 25, 2026, 4:00 PM EDT
0.2299
+0.0059 (2.63%)
After-hours: Sep 25, 2026, 7:55 PM EDT
VivoSim Labs Revenue
VivoSim Labs had revenue of $18.00K in the quarter ending June 30, 2026, a decrease of -51.35%. This brings the company's revenue in the last twelve months to $112.00K, down -21.13% year-over-year. In the fiscal year ending March 31, 2026, VivoSim Labs had annual revenue of $131.00K, down -9.03%.
Revenue (ttm)
$112.00K
Revenue Growth
-21.13%
P/S Ratio
29.70
Revenue / Employee
$7,467
Employees
15
Market Cap
3.33M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 131.00K | -13.00K | -9.03% |
| Mar 31, 2025 | 144.00K | 35.00K | 32.11% |
| Mar 31, 2024 | 109.00K | -261.00K | -70.54% |
| Mar 31, 2023 | 370.00K | -1.13M | -75.33% |
| Mar 31, 2022 | 1.50M | - | - |
| Mar 31, 2021 | - | - | - |
| Mar 31, 2020 | 2.20M | -895.00K | -28.96% |
| Mar 31, 2019 | 3.09M | -1.51M | -32.85% |
| Mar 31, 2018 | 4.60M | 373.00K | 8.82% |
| Mar 31, 2017 | 4.23M | 2.75M | 185.23% |
| Mar 31, 2016 | 1.48M | 912.00K | 159.72% |
| Mar 31, 2015 | 571.00K | 192.00K | 50.66% |
| Mar 31, 2014 | 379.00K | -818.00K | -68.34% |
| Dec 31, 2012 | 1.20M | 228.00K | 23.53% |
| Dec 31, 2011 | 969.00K | - | - |
| Jun 30, 2011 | - | - | - |
| Jun 30, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HCW Biologics | 6.72M |
| PMGC Holdings | 2.58M |
| SciSparc | 856.00K |
| GeoVax Labs | 852.28K |
| BioRestorative Therapies | 357.87K |
| Addex Therapeutics | 136.51K |
| Jupiter Neurosciences | 64.69K |
VIVS News
- 11 days ago - VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs - GlobeNewsWire
- 26 days ago - VivoSim Labs to Add Rat Liver Model to NAMkind Platform - GlobeNewsWire
- 7 weeks ago - VivoSim regains compliance with Nasdaq - TheFly
- 7 weeks ago - VivoSim Provides Financial and Listing Compliance Update - GlobeNewsWire
- 1 month ago - VivoSim files to sell 9.41M shares of common stock for holders - TheFly
- 2 months ago - VivoSim enters China with first commercial sales of NAMkind testing services - TheFly
- 2 months ago - VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services - GlobeNewsWire
- 2 months ago - VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor - GlobeNewsWire